Valneva Reports Increased Revenues and Strategic Advances in Vaccine Development

Tip Ranks
2025.11.20 11:30
portai
I'm PortAI, I can summarize articles.

Valneva SE reported an 8.9% revenue increase to €127 million for the first nine months of 2025, despite a net loss of €65.2 million. The company achieved financial flexibility through debt refinancing and reduced cash burn. Valneva is advancing its Lyme disease vaccine with Pfizer and its Shigella vaccine, which received FDA Fast Track designation. Analysts rate VALN stock as a Buy with an $18 target, while TipRanks' AI Analyst rates it Neutral due to mixed financial metrics.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

The latest update is out from Valneva ( (VALN) ).

On November 20, 2025, Valneva SE reported its financial results for the first nine months of 2025, highlighting an 8.9% increase in total revenues to €127.0 million compared to the same period in 2024. The company achieved significant financial flexibility through successful debt refinancing and reduced operating cash burn. Despite a net loss of €65.2 million, Valneva’s commercial portfolio showed growth, particularly in its Japanese encephalitis vaccine sales. The company is advancing its Lyme disease vaccine candidate with Pfizer, expecting Phase 3 results in 2026, and is also progressing with its Shigella vaccine candidate, which received Fast Track designation from the FDA.

The most recent analyst rating on (VALN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s overall stock score reflects a mix of positive technical momentum and strategic progress in vaccine development, offset by financial challenges. The company’s strong cash position and revenue growth are promising, but negative profitability and valuation metrics weigh on the score.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company focused on developing and commercializing vaccines for infectious diseases. The company offers a portfolio of travel vaccines, including IXIARO®/JESPECT® for Japanese encephalitis, DUKORAL® for cholera and ETEC-diarrhea, and the recently launched IXCHIQ® for chikungunya. Valneva also engages in the distribution of third-party products in select markets and is actively involved in developing vaccine candidates for Lyme disease and shigellosis.

Average Trading Volume: 69,411

Technical Sentiment Signal: Hold

Current Market Cap: $739.7M

For an in-depth examination of VALN stock, go to TipRanks’ Overview page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.